Bortezomib, Doxorubicin Hydrochloride Liposome, and Thalidomide as First-line Therapy in Treating Patients With Previously Untreated Stage I, II, or III Multiple Myeloma
Completed · Phase 2
Conditions studied: Multiple Myeloma and Plasma Cell Neoplasm
In brief
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as doxorubicin hydrochloride liposome, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Thalidomide may stop the growth of multiple myeloma by blocking blood flow to the cancer. Giving bortezomib together with doxorubicin hydrochloride liposome and thalidomide may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving bortezomib together with doxorubicin hydrochloride liposome and thalidomide works as first-line therapy in treating patients with previously untreated multiple myeloma.
Key facts
- Study ID
- NCT00523848
- Run by
- Roswell Park Cancer Institute
- People needed
- 46
- Starts
- 2006-06-01
- Expected to finish
- 2012-10-01
- Last updated by the study team
- 2017-02-23
Who can join
Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Karnofsky performance status 60-100%
- Platelet count ≥ 75,000 cells/mm\^3 (< 75,000 cells/mm\^3 secondary to extensive bone marrow disease allowed at the PI's discretion with appropriate transfusion support)
- ANC ≥ 1,000 cells/mm\^3
- Hemoglobin ≥ 8.0 g/dL (< 8 g/dL secondary to extensive bone marrow disease allowed at the PI's discretion with appropriate transfusion support)
- Creatinine clearance > 20 mL/min
- AST and ALT ≤ 2 times upper limit of normal (ULN) OR ≤ 3 times ULN (in the presence of liver metastases)
- Alkaline phosphatase ≤ 2 times ULN OR ≤ 3 times ULN (in the presence of liver metastases)
- Total bilirubin ≤ 2 times ULN OR ≤ 3 times ULN (in the presence of liver metastases)
- Ejection fraction ≥ 50% by MUGA or 2-D echocardiogram
- Negative pregnancy test
- Fertile patients must use at least 1 highly effective and 1 additional effective contraception method 4 weeks prior to, during, and 3 months after completion of study therapy
- HIV-negative
- Must have sufficient mental capacity to understand the explanation of the study and to provide informed consent
- Willingness and ability to comply with the FDA-mandated S.T.E.P.S. program
You may not qualify if…
- Pregnant or lactating
- Active, serious infections uncontrolled by antibiotics
- Any medical condition or reason that, in the investigator's opinion, makes the patient unsuitable to participate in this clinical trial
- History of hypersensitivity reactions attributed to a conventional formulation of doxorubicin hydrochloride or the components of doxorubicin hydrochloride liposome or bortezomib, boron, or mannitol
- Any of the following conditions:
- History of uncontrolled New York Heart Association class II-IV heart disease or clinical evidence of congestive heart failure
- Myocardial infarction within the past 6 months
- Uncontrolled angina
- Severe uncontrolled ventricular arrhythmias, ECG evidence of acute ischemia, or active conduction system abnormalities
- Peripheral neuropathy ≥ grade 2
- PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Where it is running
- Roswell Park Cancer Institute — Buffalo, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.